secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001104659-25-089737
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics' investor deck highlights Zervimesine Phase 3 progress
-----------------------------------------------------------------------------

- Presentation focuses on Zervimesine, a once-daily oral therapeutic for neurodegenerative diseases.
- Zervimesine is described as advancing toward Phase 3, but no specific trial dates or results disclosed.
- No financial results, guidance, or material operational updates included in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/0001104659-25-089737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/tm2525997d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-089737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer